Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming

Oncogene

Volumn 32, Issue 18, 2013, Pages 2249-2260

  Zhang, X ^a   Cruz, F D ^a   Terry, M ^a   Remotti, F ^a   Matushansky, I ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

induced pluripotent stem cells; sarcoma; stem cells

Indexed keywords

KI 67 ANTIGEN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX17; TRANSCRIPTION FACTOR SOX2; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DNA METHYLATION; EMBRYOID BODY; EPIGENETICS; ERYTHROID CELL; GENE EXPRESSION; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; SARCOMA; SOMATIC CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIPOSARCOMA; MICE; MICE, SCID; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; ONCOGENES; OSTEOSARCOMA; RNA-BINDING PROTEINS; SARCOMA; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877574727     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.237     Document Type: Article

References (58)

1. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008; 132: 567-582.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
3. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K et al. In vitro reprogramming of fibroblasts into a pluripotent Es-cell-like state. Nature 2007; 448: 318-324.
4. Lengner CJ. iPS cell technology in regenerative medicine. Ann N Y Acad Sci 2010; 1192: 38-44.
5. Carette JE, Pruszak J, Varadarajan M, Blomen Va, Gokhale S, Camargo Fd et al. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039-4042.
6. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009; 122(Pt 19): 3502-3510.
7. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460: 1145-1148.
8. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 2010; 107: 40-45.
9. Tang Y, Kim M, Carrasco D, Kung Al, Chin L, Weissleder R. In vivo assessment of ras-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. Cancer Res 2005; 65: 8324-8330.
10. Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004; 18: 1875-1885.
11. Chang G, Miao Yl, Zhang Y, Liu S, Kou Z, Ding J et al. Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells. Plos One 2010; 5: E10320.
12. Yu J, Vodyanik Ma, Smuga-Otto K, Antosiewicz-Bourget J, Frane Jl, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
13. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
14. Mills J, Hricik T, Siddiqi S, Matushansky I. Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Mol Cancer Ther 2011; 10: 313-324.
15. Mills J, Matos T, Charytonowicz E, Hricik T, Castillo-Martin M, Remotti F et al. Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo. Hum Cell 2009; 22: 85-93.
16. Krause U, Seckinger A, Gregory Ca. Assays of osteogenic differentiation by cultured human mesenchymal stem cells. Methods Mol Biol 2011; 698: 215-230.
17. Feng J, Mantesso A, De Bari C, Nishiyama A, Sharpe Pt. Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci USA 2011; 108: 6503-6508.
18. Lai Rc, Choo A, Lim Sk. Derivation and characterization of human ESC-derived mesenchymal stem cells. Methods Mol Biol 2011; 698: 141-150.
19. Lu SJ, Feng Q, Park JS, Lanza R. Directed differentiation of red blood cells from human embryonic stem cells. Methods Mol Biol 2010; 636: 105-121.
20. Lu SJ, Feng Q, Park JS, Vida L, Lee BS, Strausbauch M et al. Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood 2008; 112: 4475-4484.
21. Merryweather-Clarke AT, Atzberger A, Soneji S, Gray N, Clark K, Waugh C et al. Global gene expression analysis of human erythroid progenitors. Blood 2011; 117: e96-e108.
22. Ma F, Ebihara Y, Umeda K, Sakai H, Hanada S, Zhang H et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci USA 2008; 105: 13087-13092.
23. Barrios C, Castresana JS, Kreicbergs A. Clinicopathologic correlations and shortterm prognosis in musculoskeletal sarcoma with C-Myc oncogene amplification. Am J Clin Oncol 1994; 17: 273-276.
24. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar Ma et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117: 3248-3257.
25. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-326.
26. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev 2007; 8: 263-271.
27. Ohm JE, Mcgarvey KM, Yu X, Cheng L, Schuebel KE, Cope L et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39: 237-242.
28. Koche RP, Smith ZD, Adli M, Gu H, Ku M, Gnirke A et al. Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell 2011; 8: 96-105.
29. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev 2010; 24: 2239-2263.
30. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
31. Han J, Sachdev PS, Sidhu KS. A combined epigenetic and non-genetic approach for reprogramming human somatic cells. Plos One 2010; 5: E12297.
32. Higgins ME, Claremont M, Major JE, Sander C, Lash AE. Cancergenes: a gene selection resource for cancer genome projects. Nucleic Acids Res 2007; 35: D721-D726.
33. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008; 454: 49-55.
34. Zhang B, Chen B, Wu T, Tan Y, Qiu S, Xuan Z et al. Estimating the quality of reprogrammed cells using ES cell differentiation expression patterns. Plos One 2011; 6: E15336.
35. Matushansky I, Hernando E, Socci ND, Matos T, Mills J, Edgar MA et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 2008; 172: 1069-1080.
36. Glauche I, Moore K, Thielecke L, Horn K, Loeffler M, Roeder I. Stem cell proliferation and quiescence-two sides of the same coin. Plos Comput Biol 2009; 5: E1000447.
37. Ogawa M, Porter PN, Nakahata T. Renewal and commitment to differentiation of hemopoietic stem cells (an interpretive review). Blood 1983; 61: 823-829.
38. Giebel B, Punzel M. Lineage development of hematopoietic stem and progenitor cells. Biol Chem 2008; 389: 813-824.
39. Siddiqi S, Mills J, Matushansky I. Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. Curr Stem Cell Res Ther 2010; 5: 63-73.
40. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007; 1: 101-112.
41. Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009; 41: 968-976.
42. Okita K, Hong H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 2010; 5: 418-428.
43. Gore A, Li Z, Fung Hl, Young JE, Agarwal S, Antosiewicz-Bourget J et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471: 63-67.
44. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
45. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471: 68-73.
46. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8: 106-118.
47. Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7: 521-531.
48. Theunissen TW, Van Oosten AL, Castelo-Branco G, Hall J, Smith A, Silva JC. Nanog overcomes reprogramming barriers and induces pluripotency in minimal conditions. Curr Biol 2011; 21: 65-71.
49. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. Plos Biol 2008; 6: E253.
50. Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010; 6: 71-79.
51. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E. Retinoid target genes in acute promyelocytic leukemia. Leukemia 2003; 17: 1723-1730.
52. Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, Cordon-Cardo C et al. Ppargamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 2012; 122: 886-898.
53. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-3007.
54. Pomerantz JH, Mukherjee S, Palermo AT, Blau HM. Reprogramming to a muscle fate by fusion recapitulates differentiation. J Cell Sci 2009; 122(Pt 7): 1045-1053.
55. West FD, Machacek DW, Boyd Nl, Pandiyan K, Robbins KR, Stice SL. Enrichment and differentiation of human germ-like cells mediated by feeder cells and basic fibroblast growth factor signaling. Stem Cells 2008; 26: 2768-2776.
56. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7: 618-630.
57. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26: 1269-1275.
58. Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, Gu H et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol 2010; 28: 1106-1114.